Abatacept in combination with ATLG reduces acute GvHD incidence and improves outcomes of children transplanted from mismatched unrelated donors: a real-world, multicenter, retrospective study
In brief
Pediatric cancer transplants with six-dose abatacept had 7% relapse versus 40%
In this retrospective study of children and young adults receiving mismatched-donor transplants, grade II to IV acute graft-versus-host disease occurred in 24% overall. Among patients with cancer, relapse was 7% with six abatacept doses versus 40% with four, alongside better 3-year survival. Because treatment was not randomized, the apparent benefit needs confirmation; chronic graft-versus-host disease rates did not differ by schedule.
- Journal
- Transplantation and cellular therapy (Q1)
- Published
- 9 October 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Francesco Quagliarella, Matteo Becci, Jochen Buechner, Marco Becilli, Marco Zecca, Maria Ester Bernardo, et al.
- PMID
- 42855012
- DOI
- 10.1016/j.jtct.2026.10.009
Why clinicians should know about it
- Picked for Hematology (paper of the day, 11 October 2026): ABA+ATLG lowers acute GvHD, improves survival in pediatric HCT
Abstract
BACKGROUND: The use of HLA-mismatched donors has been associated with increased risk of both acute and chronic Graft versus Host Disease (GvHD). The use of abatacept (ABA) reduces the risk of acute GvHD. ABA data in pediatric patients and in combination with serotherapy are limited. OBJECTIVE: We hypothesized that adding ABA to the standard European GvHD prophylaxis with calcineurin inhibitor (CNI), short-course methotrexate (MTX) and anti-T-lymphocyte globulins (ATLG) would result in a lower incidence of acute GvHD and improve survival outcomes. STUDY DESIGN: We retrospectively analyzed data from 8 pediatric centers on consecutive patients transplanted from an HLA-mismatched unrelated donor who received ABA. The drug was added to standard GvHD pharmacological prophylaxis, including CNI, MTX and ATLG. Besides the classical 4-dose schedule, extended administration was performed (6 total doses). RESULTS: Between February/2021 and July/2025, 91 pediatric/young adult patients with malignant or non-malignant diseases received ABA. The cumulative incidence (CI) of grade II-IV and grade III-IV acute GvHD were 24.4% and 6.9%, respectively. CI of grade II-IV acute GvHD was higher, but not statistically significant, in patients who received four doses of ABA as compared to those treated with six doses (38.1% vs 19.9%, p=0.08). CI of chronic GvHD was 29.6%, with no difference according to ABA schedule. In children with malignant diseases, relapse incidence was lower in patients receiving extended-course ABA compared to those who received 4 doses (6.9% vs 39.7%, p=0.008), resulting in improved 3-year event-free survival (88.2% vs 44.9%, p=0.001) and overall survival (OS, 91% vs 72.8 p=0.008). Among the 35 patients with non-malignant diseases, OS was 95.7%. No increased incidence of infections was observed, with the exception of EBV reactivation. Finally, we compared the outcomes of the malignant group with those of a comparable cohort from AIEOP-HSCT network, transplanted with the same approach (with the exception of ABA). Three-year GVHD/Relapse-Free Survival was 59.3% for the present cohort and 35.8% for the historical one (p=0.006). CONCLUSIONS: Our data indicate that in patients undergoing mismatched HSCT, ABA, added to a standard GvHD prophylaxis, is a suitable option for preventing GvHD, without impairing the graft-versus-leukemia effect.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.